Victor L Villemagne Selected Research

Copper

1/2018	Targeting metals rescues the phenotype in an animal model of tauopathy.
1/2018	Effect of Structural Modifications to Glyoxal-bis(thiosemicarbazonato)copper(II) Complexes on Cellular Copper Uptake, Copper-Mediated ATP7A Trafficking, and P-Glycoprotein Mediated Efflux.
10/2013	Diagnostic imaging agents for Alzheimer's disease: copper radiopharmaceuticals that target Aβ plaques.
1/2013	Longitudinal analysis of serum copper and ceruloplasmin in Alzheimer's disease.
8/2010	A copper radiopharmaceutical for diagnostic imaging of Alzheimer's disease: a bis(thiosemicarbazonato)copper(II) complex that binds to amyloid-beta plaques.
1/2010	Bis(thiosemicarbazonato) Cu-64 complexes for positron emission tomography imaging of Alzheimer's disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Victor L Villemagne Research Topics

Disease

210	Alzheimer Disease (Alzheimer's Disease) 05/2024 - 08/2005
105	Cognitive Dysfunction 05/2024 - 11/2008
78	Dementia (Dementias) 05/2024 - 08/2007
27	Atrophy 07/2022 - 03/2010
17	Disease Progression 11/2023 - 07/2012
10	Parkinson Disease (Parkinson's Disease) 11/2023 - 09/2009
9	Neurodegenerative Diseases (Neurodegenerative Disease) 05/2024 - 03/2012
8	Gliosis 05/2024 - 04/2005
7	Amyloidosis 06/2023 - 01/2013
7	Amyloid Plaque 06/2023 - 01/2010
7	Frontotemporal Dementia (Semantic Dementia) 01/2018 - 09/2011
4	Tauopathies 01/2021 - 01/2014
4	Parkinsonian Disorders (Parkinsonism) 01/2021 - 11/2017
4	Primary Progressive Aphasia 11/2018 - 10/2015
4	Proteostasis Deficiencies 07/2018 - 11/2009
3	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2023 - 06/2014
3	Neuroinflammatory Diseases 01/2023 - 04/2013
3	Corticobasal Degeneration 01/2021 - 10/2015
3	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2020 - 04/2014
3	Ischemic Stroke 01/2016 - 12/2010
2	Schizophrenia (Dementia Praecox) 10/2021 - 01/2006
2	Cerebral Amyloid Angiopathy (Congophilic Angiopathy) 01/2021 - 12/2010
2	Obstructive Sleep Apnea 01/2020 - 01/2018
2	Neoplasms (Cancer) 10/2018 - 01/2018
2	Memory Disorders (Memory Loss) 11/2017 - 03/2011
2	Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy) 05/2015 - 08/2011
2	Hemorrhage 01/2014 - 12/2010
2	Frontotemporal Lobar Degeneration (Degeneration, Frontotemporal Lobar) 10/2012 - 08/2011
1	Substance-Related Disorders (Drug Abuse) 11/2023
1	Craniocerebral Trauma (Head Injury) 11/2023
1	Clinical Deterioration 01/2023
1	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 01/2023
1	Insulin Resistance 01/2022
1	Coronary Artery Disease (Coronary Atherosclerosis) 01/2022

Drug/Important Bio-Agent (IBA)

166	Amyloid (Amyloid Fibrils)IBA 05/2024 - 11/2008
110	Biomarkers (Surrogate Marker)IBA 05/2024 - 02/2006
35	Amyloid beta-PeptidesIBA 07/2023 - 04/2005
28	Apolipoproteins E (ApoE)IBA 03/2024 - 01/2011
26	2- (4'- (methylamino)phenyl)- 6- hydroxybenzothiazole (Pittsburgh compound B)IBA 07/2023 - 04/2007
14	ApolipoproteinsIBA 03/2024 - 12/2013
9	Proteins (Proteins, Gene)FDA Link 01/2022 - 04/2013
8	LigandsIBA 01/2021 - 11/2009
7	4- (N- methylamino)- 4'- (2- (2- (2- fluoroethoxy)ethoxy)ethoxy)stilbeneIBA 07/2023 - 02/2008
6	CopperIBA 01/2018 - 01/2010
5	LipidsIBA 11/2022 - 05/2017
5	Vesicular Monoamine Transport Proteins (Vesicular Monoamine Transporter)IBA 10/2020 - 02/2010
5	Peptides (Polypeptides)IBA 05/2017 - 01/2011
4	Monoamine Oxidase (MAO)IBA 05/2024 - 01/2022
4	Glial Fibrillary Acidic ProteinIBA 01/2023 - 11/2021
4	Glucose (Dextrose)FDA LinkGeneric 01/2023 - 08/2002
4	SynucleinsIBA 01/2021 - 11/2009
4	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 11/2017 - 04/2007
3	Blood Proteins (Serum Proteins)IBA 01/2022 - 01/2017
3	Neurotransmitter Agents (Neurotransmitter)IBA 01/2022 - 11/2009
3	RadiopharmaceuticalsIBA 01/2021 - 08/2010
3	THK5351IBA 04/2020 - 11/2017
3	tau Proteins (tau Protein)IBA 01/2019 - 01/2010
3	Brain-Derived Neurotrophic Factor (BDNF)IBA 11/2017 - 11/2013
3	florbenazine F 18IBA 11/2017 - 07/2011
3	2- (4- aminophenyl)- 6- (2- fluoroethoxy)quinolineIBA 05/2014 - 04/2011
2	7- (6- fluoropyridin- 3- yl)- 5H- pyrido(4,3- b)indoleIBA 05/2024 - 01/2019
2	Hydrocortisone (Cortisol)FDA LinkGeneric 01/2024 - 01/2017
2	Cholinergic Agents (Cholinergics)IBA 12/2023 - 01/2022
2	Threonine (L-Threonine)FDA Link 06/2023 - 10/2021
2	HDL LipoproteinsIBA 10/2022 - 01/2020
2	quinolineIBA 10/2022 - 11/2017
2	CholesterolIBA 10/2022 - 01/2020
2	KynurenineIBA 01/2022 - 10/2021
2	Protein Isoforms (Isoforms)IBA 01/2021 - 01/2019
2	Protein AggregatesIBA 01/2021 - 01/2016
2	AntibodiesIBA 01/2021 - 01/2014
2	CarbonIBA 01/2019 - 08/2007
2	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 01/2018 - 08/2013
2	StilbenesIBA 03/2015 - 08/2010
2	AD 20 (AD-20)IBA 01/2012 - 07/2011
2	alpha-SynucleinIBA 09/2009 - 09/2007
2	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 01/2006 - 08/2005
1	Peptide Hydrolases (Proteases)FDA Link 03/2024
1	Protease Inhibitors (Protease Inhibitor)IBA 03/2024
1	Oxidoreductases (Dehydrogenase)IBA 01/2024
1	formic acid (formate)IBA 06/2023
1	flutemetamolIBA 06/2023
1	Prealbumin (Transthyretin)IBA 06/2023
1	Immunoglobulin Light Chains (Immunoglobulin Light Chain)IBA 06/2023
1	AminesIBA 01/2023
1	Vesicular Glutamate Transport ProteinsIBA 01/2023
1	A 7 (A-7)IBA 01/2023
1	neurabinIBA 01/2023
1	Messenger RNA (mRNA)IBA 01/2023
1	LDL CholesterolIBA 10/2022
1	HDL CholesterolIBA 10/2022
1	LDL Lipoproteins (beta Lipoproteins)IBA 10/2022
1	Scavenger Receptors (Scavenger Receptor)IBA 07/2022
1	IntegrinsIBA 07/2022

Therapy/Procedure

8	Therapeutics 01/2018 - 06/2006
4	Secondary Prevention 01/2020 - 01/2013
2	Immunotherapy 01/2014 - 09/2011
1	Contraindications 11/2023
1	Precision Medicine 03/2023
1	Denervation 01/2022